GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.
The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.
GSK said it expects to take a charge of £1.8 billion ($2.3 billion) in its third-quarter results in relation to the ...
British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to ...
WJET Erie on MSN2d
Drugmaker to settle nearly 80,000 Zantac lawsuits for up to $2.2 billionUK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer ...
2don MSN
British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to ...
Tens of thousands of Americans are in line to share $2.2bn (£1.7bn) after GSK agreed a settlement over claims its indigestion ...
MT Newswires on MSN3d
GSK Reaches up to $2.2 Billion Zantac Litigation Settlement in USGSK (GSK) on Wednesday announced a settlement resolving a bundle of 80,000 product liability cases in the US that alleged its over-the-counter heartburn medication, Zantac, increased the risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback